ArticleOncotarget2019
Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models.
Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 59 citations in OpenAlex.
- Single-cell landscape of peripheral and tumor-infiltrating immune cells in HPV-negative HNSCC.Oncoimmunology · 2026Article
- Mechanism of Qiling Fuzheng Qingjie granules in alleviating doxorubicin-induced T cell immune dysfunction via mitochondrial energy metabolism.Chinese medicine · 2026Article
- KLRG1 silencing increases the efficacy of CAR NK cell therapy against colon cancer via SHP-2/ZAP-70/NF-κB signal pathway.Journal of translational medicine · 2026Article
- Targeting Blimp-1 in T cells results in activation of T-bet-mediated control of immunosuppression in lung cancer.Cancer immunology, immunotherapy : CII · 2026Article
- E-cadherin expression promotes tumor growth via KLRG1-dependent pathways.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Targeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte subsets.Journal for immunotherapy of cancer · 2026Article
- Spatially microdissected profiling of tonsillar germinal centers reveals a KLRG1-enriched immune signature in IgA nephropathy.Frontiers in immunology · 2026Article
- Identification and regulation of circulating tumor-TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancer.JCI insight · 2025Article
- KLRG1 expression induces functional exhaustion of NK cells in colorectal cancer patients.Cancer immunology, immunotherapy : CII · 2025Article
- Altered CD4 T cell response in oligometatastic non-small cell lung cancer brain metastasis.Acta neuropathologica communications · 2025Article
- NK Cell Senescence in Cancer: From Molecular Mechanisms to Therapeutic Opportunities.Aging and disease · 2025Review
- Article
- Single-cell RNA-sequencing of human spleens reveals an IDO-1Cancer letters · 2024Article
- The role of KLRG1: a novel biomarker and new therapeutic target.Cell communication and signaling : CCS · 2024Review
- KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Genome-wide analyses reveal the contribution of somatic variants to the immune landscape of multiple cancer types.PLoS genetics · 2024Article
- Genetic architecture of the acute and persistent immune cell response after radiation exposure.Cell genomics · 2023Article
- KLRG1 expression on natural killer cells is associated with HIV persistence, and its targeting promotes the reduction of the viral reservoir.Cell reports. Medicine · 2023Article
- Towards a better preclinical cancer model - human immune aging in humanized mice.Immunity & ageing : I & A · 2023Article
- KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.Journal for immunotherapy of cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKLRG1 is a lymphocyte co-inhibitory, or immune checkpoint, receptor expressed predominantly on late-differentiated effector and effector memory CD8+ T and NK cells. Targeting of KLRG1 neutralization in murine cancer models has not previously been reported.
methodsWe studied KLRG1 expression in human blood and tumor samples from available genomic datasets. Anti-KLRG1 neutralizing antibody was studied in the murine 4T1 breast cancer as monotherapy, and in the MC38 colon cancer and B16F10 melanoma models as combination therapy with anti-PD-1 antibody.
resultsIn human blood and tumor samples, KLRG1 expression is aligned with cytotoxic T and NK cell differentiation, and upregulated in human tumor samples after a variety of therapies, potentially contributing to adaptive resistance. In
conclusionsThese studies provide the first evidence that inhibition of the KLRG1 pathway enhances immune control of cancer in murine models, and provide target validation for KLRG1 targeting of human cancer. The mechanism of efficacy of KLRG1 blockade in murine models remains to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.